The clinical-stage monoclonal protein, Xentuzumab – formerly designated BI 836845 – represents a promising effort by Astellas Pharma targeting PD-1. The development initially focused on solid tumor treatments, but https://dillanaajt025955.pointblog.net/xentuzumab-a-deep-analysis-into-bi-836845-and-its-progress-94511284